Market Overview

UPDATE: Credit Suisse Downgrades Amgen to Neutral; Upgrade Catalysts Have Passed

Related AMGN
Are There Any Winners Left In The Biotech Space?
Is Illumina Worth Adding To Your Portfolio?
The Tech Industry is Vanishing Before Our Eyes (Fox Business)

Credit Suisse downgraded Amgen (NASDAQ: AMGN) from Outperform to Neutral and lowered the price target to $90.00.

Credit Suisse commented, "The principal reason for our downgrade is that the 3 key elements of our July 2012 report entitled "Upgrading to Outperform = Agency cost + operational gearing + defensive macro call" have been realized, in our veiw [sic] (Please refer to our note,"Upgrading to Outperform = Agency cost + Operational gearing + Defensive macro call", published on July 25). We believe investors are likely looking for fundamental (i.e., pipeline and strategy) improvements/triggers in 2013. We have made no changes to our P&L estimates."

Amgen closed at $82.07 on Friday.

Latest Ratings for AMGN

DateFirmActionFromTo
Oct 2014CitigroupMaintainsBuy
Oct 2014Credit SuisseMaintainsNeutral
Oct 2014NomuraUpgradesNeutralBuy

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (AMGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters